Table 2.

Hazard ratios for any serious infection in users of tumour necrosis factor-α (TNF-α) inhibitors compared with matched non-users within 90 days and 365 days risk periods and according to sex and inflammatory bowel disease subtype

Variables	Users of TNF-α inhibitors			Non-users of TNF-α inhibitors		Hazard ratio (95% CI)
	No of patients	No of events		No of patients	No of events
90 days risk period
Main analysis	1543	51		1543	33	1.63 (1.01 to 2.63)
Sex:
Men	656	17		656	17	1.20 (0.57 to 2.50)
Women	887	34		887	16	2.08 (1.09 to 3.96)
Inflammatory bowel disease subtype:
Ulcerative colitis	876	32		876	18	1.83 (0.96 to 3.47)
Crohn’s disease	667	19		667	15	1.39 (0.67 to 2.88)
365 days risk period
Main analysis	1543	107		1543	78	1.27 (0.92 to 1.75)
Sex:
Men	656	48		656	36	1.18 (0.73 to 1.91)
Women	887	59		887	42	1.34 (0.87 to 2.08)
Inflammatory bowel disease subtype:
Ulcerative colitis	876	67		876	38	1.45 (0.92 to 2.27)
Crohn’s disease	667	40		667	40	1.05 (0.65 to 1.69)